CME: Pediatric growth hormone deficiency (PGHD) and related disorders: Updates in recognition and treatment
ACCREDITATION EXPIRED: October 14, 2023
Activity Description / Statement of Need:
In this online, self-learning activity:
Growth hormone deficiency (GHD) is characterized by inadequate secretion of growth hormone by the pituitary gland. The condition may arise from a variety of causes, including tumors, radiation, medications, traumatic brain injury, or genetic defects. In children, GHD is characterized by pronounced short stature, defined as 2 or more standard deviations from the mean based on age and sex. Because short stature may be caused by a variety of other factors, including genetics, hypothyroidism, and Turner syndrome, estimating the prevalence of GHD in the pediatric population is challenging. Studies suggest that GHD may occur in 1 out of every 4,000 children. There are also related conditions whose features overlap, including idiopathic short stature (ISS), and primary insulin-like growth factor-I deficiency (PIGFD), complicating diagnosis.
This program has been designed to bring HCPs’ knowledge of the rationale behind management of pediatric GHD up to date and to enhance their competence and practice in caring for pediatric patients with GHD. Topics addressed will include: clinical presentation, diagnostic tests, and safety and efficacy of present and emerging therapy, including dose selection, monitoring, transition into adulthood, and providing patient-centered care.
Target Audience:
The following HCPs: Endocrinologists, pediatricians, and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in endocrinology; and any other HCPs with an interest in or who clinically encounter patients with GHD.
Commercial Support Disclosure: This program is supported by an educational grant from Ipsen.
This activity is free of charge.
Release Date: October 14, 2021 -- Expiration Date: October 14, 2023
Faculty: Michael Gottschalk, MD, PhD
Agenda
|
Introduction, disclosures |
|
Introduction
|
|
Treatment options available for GHD in pediatric patients
· Efficacy and safety · Recent literature · Biosimilar considerations · Monitoring parameters · Investigational agents: long-acting (e.g., somapacitan, lonapegsomatropin)
|
|
Summary, conclusions, and best practice recap |
Learning Objectives
By the end of the session the participant will be able to:
- Describe the importance of timely recognition, referral, screening, and diagnosis of GHD, ISS, and PIGFD in children.
- Summarize current recommendations for the diagnosis of pediatric GHD and related disorders.
- Recall present and investigational pharmacotherapeutic options for treatment of pediatric GHD regarding safety, efficacy, transitions of care into adulthood, and other relevant considerations.
- Formulate treatment strategies for pediatric patients with GHD and related disorders, and describe best practices for tracking patient progress.
Accreditation
ACCME Activity #201759867
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure:
Michael Gottschalk, MD, PhD, Clinical Professor of Pediatrics, Chief, Division of Endocrinology/Diabetes, Department of Pediatrics, University of California, San Diego School of Medicine, has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty will discuss off-label uses.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Ipsen.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
The current and emerging landscape of pediatric growth hormone deficiency (GHD) pharmacotherapy
Child and adolescent Crohn’s disease: Updates in medical and nutritional strategies
Osteoporosis in men: An underappreciated and under-treated condition